Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

VIGILANT Targeting ER Import And Activation Of Viral Glycoproteins: Towards Broad-Spectrum Antivirals

Coordinator
Deutsches Primatenzentrum GmbH, Germany
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€7.5m
Total cost
€7.5m
Partners
10 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101191811

What the project is doing

In the project's own words, from its summary on CORDIS.

The VIGILANT consortium is dedicated to tackling the global threat posed by emerging viruses, exemplified by the COVID-19 pandemic and the Ebola epidemic in Western Africa. These events have emphasized the profound impact of such viruses on human health and economic stability. Moreover, anthropogenic factors, notably climate change, will result in an increase in the frequency of outbreaks caused by these viruses in the future.

To address this vulnerability, the VIGILANT consortium pursues the development of antivirals with broad-spectrum activity. Pioneering research conducted by the consortium has identified the inhibition of the Sec61 channel and virus-activating host proteases as a promising strategy. The consortium's efforts are centered on addressing priority diseases defined by the World Health Organization due to their epidemic potential and the lack of countermeasures.

Thus, the VIGILANT consortium aims to provide new insights into the protease dependence of emerging viruses, including Ebola virus, Marburg virus, Nipah virus, Zika virus, and Chikungunya virus. Furthermore, VIGILANT will develop inhibitors of the virus-activating proteases furin and cathepsin B/L that are safe and exert broad and potent antiviral activity in cell culture and animal models and are thus ready for clinical evaluation.

Furthermore, VIGILANT will devise inhibitors targeting Sec61 and will determine breadth of antiviral activity and potential resistance mechanisms. To achieve these ambitious goals, VIGILANT has assembled an array of partners with unique resources and expertise. These partners have demonstrated success in inhibitor development, protease profiling, protein structure determination, and analysis of antivirals. By leveraging their collective capabilities, the VIGILANT consortium aims to provide important insights into ER import and activation of viral glycoproteins and to bring about a quantum leap in pandemic preparedness – the development of broad-spectrum antiviral

Who is involved

OrganisationCityCountryRole
Deutsches Primatenzentrum GmbHGottingenGermanyCoordinator
Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer TiergesundheitGreifswald-Insel RiemsGermanyParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Koninklijke Nederlandse Akademie Van Wetenschappen - KnawAmsterdamNetherlandsParticipant
Karolinska InstitutetStockholmSwedenParticipant
Lunds UniversitetLundSwedenParticipant
Institut Jozef StefanLjubljanaSloveniaParticipant
National Institute of Allergy and Infectious DiseasesRockvilleUnited StatesAssociatedpartner
University of FloridaGainesvilleUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI